MECCA - A DEVELOPMENTAL, DOSE-INTENSIVE, NON-CROSS-RESISTANT PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED OVARIAN-CANCER

Twenty-nine women, ages 30-58 years, with advanced ovarian carcinoma w ere treated with a developmental combination chemotherapy regimen cons isting of mitomycin C, etoposide, cisplatin, and carboplatin (MECCA). This protocol utilized the concepts of dose intensity, front-end loadi ng, non-cross-resistance, and synergy. The median overall survival was 37 months with a 27% 5-year survival; the median failure-free surviva l was 15 months with a 14% 5-year failure-free rate. The predominant t oxicity was hematologic and there was one toxic death (cardiac failure ). The overall survival results are superior to our previous experienc e. (C) 1996 Academic Press, Inc.